GAIN THERAPEUTICS INC

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

30 May 2024 06:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

14 May 2024 06:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

24 Apr 2024 08:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

08 Apr 2024 08:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

01 Apr 2024 08:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at Public Ventures Discovery Day

15 Mar 2024 13:30:34 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

27 Feb 2024 13:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

14 Feb 2024 11:29:34 By Nasdaq GlobeNewswire

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 08:56:04 By Nasdaq GlobeNewswire

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

04 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

01 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

24 Nov 2023 12:01:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

21 Nov 2023 07:54:48 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

20 Nov 2023 15:03:43 By Nasdaq GlobeNewswire